JP2021514369A5 - - Google Patents
Info
- Publication number
- JP2021514369A5 JP2021514369A5 JP2020544005A JP2020544005A JP2021514369A5 JP 2021514369 A5 JP2021514369 A5 JP 2021514369A5 JP 2020544005 A JP2020544005 A JP 2020544005A JP 2020544005 A JP2020544005 A JP 2020544005A JP 2021514369 A5 JP2021514369 A5 JP 2021514369A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- seq
- lma
- amino acid
- acid sequence
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024079382A JP7798956B2 (ja) | 2018-02-20 | 2024-05-15 | 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018900534A AU2018900534A0 (en) | 2018-02-20 | Composition and method | |
| AU2018900534 | 2018-02-20 | ||
| PCT/AU2019/050137 WO2019161443A1 (en) | 2018-02-20 | 2019-02-20 | Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024079382A Division JP7798956B2 (ja) | 2018-02-20 | 2024-05-15 | 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021514369A JP2021514369A (ja) | 2021-06-10 |
| JP2021514369A5 true JP2021514369A5 (https=) | 2022-03-02 |
| JPWO2019161443A5 JPWO2019161443A5 (https=) | 2022-03-02 |
| JP7490559B2 JP7490559B2 (ja) | 2024-05-27 |
Family
ID=67686653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544005A Active JP7490559B2 (ja) | 2018-02-20 | 2019-02-20 | 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質 |
| JP2024079382A Active JP7798956B2 (ja) | 2018-02-20 | 2024-05-15 | 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024079382A Active JP7798956B2 (ja) | 2018-02-20 | 2024-05-15 | 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11447571B2 (https=) |
| EP (1) | EP3755724A4 (https=) |
| JP (2) | JP7490559B2 (https=) |
| KR (1) | KR102824611B1 (https=) |
| CN (1) | CN111918879B (https=) |
| AU (2) | AU2019225446B2 (https=) |
| BR (1) | BR112020017018A2 (https=) |
| CA (1) | CA3091711A1 (https=) |
| SG (1) | SG11202007925SA (https=) |
| WO (1) | WO2019161443A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250326864A1 (en) * | 2022-06-13 | 2025-10-23 | Paradox Immunotherapeutics Inc. | Monoclonal antibodies targeting conformation-specific epitopes of immunoglobulin light chains of the lambda subclass |
| WO2025236034A1 (en) * | 2024-05-13 | 2025-11-20 | HaemaLogiX Ltd | Anti-lma binding proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ548921A (en) | 2004-02-27 | 2008-09-26 | Immune System Therapeutics Ltd | Target for B-cell disorders |
| US20100187181A1 (en) * | 2009-01-29 | 2010-07-29 | Sortwell Edwin T | Method for Dispersing and Aggregating Components of Mineral Slurries |
| WO2010115238A1 (en) * | 2009-04-07 | 2010-10-14 | Immune System Therapeutics Ltd | Method for treating immune disorders |
| GB201203938D0 (en) * | 2012-03-06 | 2012-04-18 | Binding Site Group The Ltd | Assay system |
-
2019
- 2019-02-20 BR BR112020017018-6A patent/BR112020017018A2/pt unknown
- 2019-02-20 CN CN201980012636.9A patent/CN111918879B/zh active Active
- 2019-02-20 EP EP19758107.7A patent/EP3755724A4/en active Pending
- 2019-02-20 US US16/970,991 patent/US11447571B2/en active Active
- 2019-02-20 SG SG11202007925SA patent/SG11202007925SA/en unknown
- 2019-02-20 KR KR1020207027033A patent/KR102824611B1/ko active Active
- 2019-02-20 WO PCT/AU2019/050137 patent/WO2019161443A1/en not_active Ceased
- 2019-02-20 CA CA3091711A patent/CA3091711A1/en active Pending
- 2019-02-20 AU AU2019225446A patent/AU2019225446B2/en active Active
- 2019-02-20 JP JP2020544005A patent/JP7490559B2/ja active Active
-
2021
- 2021-04-06 AU AU2021202092A patent/AU2021202092A1/en not_active Abandoned
-
2022
- 2022-08-12 US US17/819,483 patent/US12435158B2/en active Active
-
2024
- 2024-05-15 JP JP2024079382A patent/JP7798956B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025160458A5 (https=) | ||
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| JP2021515798A5 (https=) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2017504578A5 (https=) | ||
| JP2021530244A5 (https=) | ||
| JP2017521054A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP2022500455A5 (https=) | ||
| JP2016529213A5 (https=) | ||
| JP2021514369A5 (https=) | ||
| JPWO2019175368A5 (https=) | ||
| JPWO2022111425A5 (https=) | ||
| JPWO2020023644A5 (https=) | ||
| JPWO2021224913A5 (https=) | ||
| JPWO2020028428A5 (https=) | ||
| JPWO2019161443A5 (https=) | ||
| JPWO2021207072A5 (https=) | ||
| JPWO2022232035A5 (https=) | ||
| JPWO2023170474A5 (https=) | ||
| JPWO2020076790A5 (https=) | ||
| JPWO2021147829A5 (https=) | ||
| JPWO2021119531A5 (https=) |